Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5

Area of Science:

• Molecular Biology
• Cancer Research
• Biochemistry

Background:

• Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis via extrinsic pathways.
• TRAIL's therapeutic potential is limited by cancer cell resistance.
• TRAIL interacts with five receptors, including two death receptors (DR4, DR5) and three decoy receptors (DcR1, DcR2, OPG).

Purpose of the Study:

• To design and express DR5-selective TRAIL variants (DR5-A and DR5-B).
• To investigate the binding affinities of these variants to TRAIL receptors.
• To evaluate the efficacy of these variants in inducing apoptosis in cancer cell lines.

Main Methods:

• Design and expression of DR5-selective TRAIL variants (DR5-A, DR5-B) in Escherichia coli.
• Measurement of dissociation constants between TRAIL variants and all five TRAIL receptors.
• Assessment of apoptosis induction in various cancer cell lines, including drug-resistant cells.

Main Results:

• DR5-A and DR5-B variants exhibit minimal interaction with DR4, DcR1, DcR2, and OPG receptors.
• These selective TRAIL variants demonstrate enhanced apoptosis induction compared to wild-type TRAIL.
• DR5-A and DR5-B, combined with cytoskeleton-targeting drugs, induce apoptosis in resistant Hela cells overexpressing Bcl-2.

Conclusions:

• Novel DR5-selective TRAIL variants (DR5-A, DR5-B) have been successfully engineered.
• These variants show high selectivity for DR5 and improved efficacy in inducing cancer cell apoptosis.
• The selective TRAIL variants offer a promising tool for studying TRAIL-induced apoptosis and developing cancer therapies.